Cost of Illness Analysis of Invasive Meningococcal Disease Caused by Neisseria Meningitidis Serogroup B in the Netherlands-a Holistic Approach.
Cost of illness
Direct and indirect costs
Economic burden
Invasive meningococcal disease
Netherlands
Serogroup B meningococcal disease
Short- and long-term sequelae
Journal
Infectious diseases and therapy
ISSN: 2193-8229
Titre abrégé: Infect Dis Ther
Pays: New Zealand
ID NLM: 101634499
Informations de publication
Date de publication:
16 Feb 2024
16 Feb 2024
Historique:
received:
03
08
2023
accepted:
05
12
2023
medline:
17
2
2024
pubmed:
17
2
2024
entrez:
17
2
2024
Statut:
aheadofprint
Résumé
Invasive meningococcal disease (IMD) caused by Neisseria meningitidis is a rapidly progressing, rare disease that often presents as meningitis or sepsis. It mostly affects infants and adolescents, with high fatality rates or long-term sequelae. In the Netherlands, serogroup B (MenB) is most prevalent. We aimed to estimate the economic burden of MenB-related IMD between 2015 and 2019, including direct and indirect medical costs from short- and long-term sequelae, from a societal perspective. IMD incidence was based on laboratory-based case numbers from the Netherlands Reference Laboratory for Bacterial Meningitis (Amsterdam UMC, Amsterdam, the Netherlands); there were 74 MenB cases on average per year in the study period 2015-2019. Case-fatality rate (3.8%) and percentage of patients discharged with sequelae (46%) were derived from literature. Direct costs included treatment costs of the acute phase, long-term sequelae, and public health response. Indirect costs were calculated using the human capital (HCA) and friction costs (FCA) approaches, in which productivity losses were estimated for patients and parents during the acute and sequelae phases. Costs were discounted by 4% yearly. Estimated costs due to MenB IMD in an annual cohort were €3,094,199 with FCA and €9,480,764 with HCA. Direct costs amounted to €2,974,996, of which 75.2% were related to sequelae. Indirect costs related to sequelae were €52,532 with FCA and €5,220,398 with HCA. Our analysis reflects the high economic burden of MenB-related IMD in the Netherlands. Sequelae costs represent a high proportion of the total costs. Societal costs were dependent on the applied approach (FCA or HCA).
Identifiants
pubmed: 38366286
doi: 10.1007/s40121-023-00903-0
pii: 10.1007/s40121-023-00903-0
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. GSK.
Références
European Centre for Disease Prevention and Control. Factsheet about meningococcal disease 2019. Available from: https://www.ecdc.europa.eu/en/meningococcal-disease/factsheet . (accessed on: Oct 26, 2021)
Olbrich KJ, Müller D, Schumacher S, Beck E, Meszaros K, Koerber F. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7(4):421–38.
doi: 10.1007/s40121-018-0213-2
pubmed: 30267220
pmcid: 6249177
Koelman DLH, van Kassel MN, Bijlsma MW, Brouwer MC, van de Beek D, van der Ende A. Changing epidemiology of bacterial meningitis since introduction of conjugate vaccines: 3 decades of national meningitis surveillance in The Netherlands. Clin Infect Dis. 2021;73(5):e1099–107.
doi: 10.1093/cid/ciaa1774
pubmed: 33247582
Control ECfDPa. Invasive meningococcal disease. Annual epidemiological report for 2017. 2016. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2017-invasive-meningococcal-disease.pdf . (accessed on: Jan 25, 2022)
Krone M, Gray S, Abad R, et al. Increase of invasive meningococcal serogroup W disease in Europe, 2013 to 2017. Euro Surveill. 2019. https://doi.org/10.2807/1560-7917.ES.2019.24.14.1800245 .
doi: 10.2807/1560-7917.ES.2019.24.14.1800245
pubmed: 30968827
pmcid: 6462787
Rijksinstituut voor Volksgezondheid en Milieu Ministerie van Volksgezondheid WeS. Meningokokken ACWY-vaccinatie 2021. Available from: https://www.rivm.nl/meningokokken/meningokokken-acwy-vaccinatie . (accessed on: Jan 25, 2022)
Netherlands HCot. Executive summary. Vaccination against meningococcal disease 2018. Available from: https://www.healthcouncil.nl/documents/advisory-reports/2018/12/19/vaccination-against-meningococcal-disease . (accessed on: Oct 26, 2021)
Gezondheidsraad. De staatssecretaris van de Volksgezondheid WeS. Vaccinatie tegen meningokokken B: update 2022. Available from: https://www.gezondheidsraad.nl/binaries/gezondheidsraad/documenten/adviezen/2022/10/12/advies-vaccinatie-tegen-meningokokken-b-update/advies-Vaccinatie-tegen-MenB_update.pdf . (accessed on: Jun, 2023)
Rodrigues FMP, Marlow R, Simões MJ, Danon L, Ladhani S, Finn A. Association of use of a meningococcus Group B vaccine with Group B invasive meningococcal disease among children in Portugal. JAMA. 2020;324(21):2187–94.
doi: 10.1001/jama.2020.20449
pubmed: 33258889
pmcid: 7709085
Rodrigues FMP, editor Protocol summary: case-control study to evaluate the effetiveness of 4CMenB vaccine in the prevention of invasive meningococcal disease in Portugal 15th European Meningococcal and Haemophilus Disease Society (EMGM) Congress; 2019; Lisbon, Portugal.
Martinón-Torres F, Banzhoff A, Azzari C, et al. Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination. J Infect. 2021;83(1):17–26.
doi: 10.1016/j.jinf.2021.04.031
pubmed: 33933528
Pouwels KB, Hak E, van der Ende A, Christensen H, van den Dobbelsteen GPJM, Postma MJ. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: crucial impact of changes in incidence. Hum Vaccin Immunother. 2013;9(5):1129–38.
doi: 10.4161/hv.23888
pubmed: 23406816
pmcid: 3899149
Stoof SP, Rodenburg GD, Knol MJ, et al. Disease burden of invasive meningococcal disease in the Netherlands between June 1999 and June 2011: a subjective role for serogroup and clonal complex. Clin Infect Dis. 2015;61(8):1281–92.
doi: 10.1093/cid/civ506
pubmed: 26123933
Scholz S, Koerber F, Meszaros K, et al. The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany. Vaccine. 2019;37(12):1692–701.
doi: 10.1016/j.vaccine.2019.01.013
pubmed: 30661834
Statline CBvdSC. Consumentenprijzen; prijsindex 2015=100 2021. Available from: https://statline.cbs.nl/Statweb/publication/?DM=SLNL&PA=83131NED . (accessed on: Oct 21, 2021)
Hakkaart-van Roijen L, van der Linden, N., Bouwmans, C., Kanters, T., Tan, S.S. Institute for Medical Technology Assessment. Erasmus Universiteit Rotterdam. Costing manual: Methodology of costing research and reference prices for economic evaluations in healthcare [in Dutch: Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg] 2016. Available from: https://www.zorginstituutnederland.nl/over-ons/publicaties/publicatie/2016/02/29/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg . (accessed on: Oct 26, 2021)
StatLine. Population; sex, age and marital status, 1st January [in Dutch: Bevolking; geslacht, leeftijd en burgerlijke staat, 1 januari] 2021. Available from: https://opendata.cbs.nl/statline/#/CBS/nl/dataset/7461BEV/table?fromstatweb . (accessed on: Oct 26, 2021)
Loenenbach AD, van der Ende A, de Melker HE, Sanders EAM, Knol MJ. The clinical picture and severity of invasive meningococcal disease serogroup W compared with other serogroups in the Netherlands, 2015–2018. Clin Infect Dis. 2020;70(10):2036–44.
doi: 10.1093/cid/ciz578
pubmed: 31556938
Welte R, van den Dobbelsteen G, Bos JM, et al. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making. Vaccine. 2004;23(4):470–9.
doi: 10.1016/j.vaccine.2004.06.019
pubmed: 15530695
Bos JM, Rümke HC, Welte R, Postma MJ, Jager JC. Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program. Vaccine. 2001;20(1–2):202–7.
doi: 10.1016/S0264-410X(01)00254-7
pubmed: 11567765
Steunpunt Passend Onderwijs. Nieuwe versies bekostigingen (v)so, residentiële leerlingen, swv po en vo, kosten kortdurend verblijf, spelregels en toelichting Kijkdozen 2020. Available from: https://www.steunpuntpassendonderwijs-povo.nl/document/versies-bekostigingen-vso-residentiele-leerlingen-swv-po-en-vo-kosten-kortdurend-verblijf-en-de-spelregels/ . (accessed on: Oct 27, 2021)
AMC AUL. Nederlands Referentie Laboratorium voor Bacteriële Meningitis (NRLBM) 2021. Available from: https://www.amc.nl/web/specialismen/medische-microbiologie-infectiepreventie-1/medische-microbiologie-infectiepreventie-1/nederlands-referentie-laboratorium-voor-bacteriele-meningitis-nrlbm.htm . (accessed on: Jan 25, 2022)
Regeling aanvullende bekostiging eduVIP2021. Available from: https://www.eduvip.nl/regeling-aanvullende-bekostiging/ . (accessed on: Oct 27, 2021)
van der Kolk A, Bouwmans CA, Schawo SJ, Buitelaar JK, van Agthoven M, Hakkaart-van Roijen L. Association between societal costs and treatment response in children and adolescents with ADHD and their parents. A cross-sectional study in the Netherlands. Springerplus. 2015;4:224.
doi: 10.1186/s40064-015-0978-7
pubmed: 26155437
pmcid: 4488238
Bénard S, Wright C, Voisine J, Olivier CW, Gaudelus J. Lifetime cost of meningococcal disease in France: scenarios of severe meningitis and septicemia with purpura fulminans. J Infect Public Health. 2016;9(3):339–47.
doi: 10.1016/j.jiph.2015.10.016
pubmed: 26688376
Pike J, Grosse SD. Friction cost estimates of productivity costs in cost-of-illness studies in comparison with human capital estimates: a review. Appl Health Econ Health Policy. 2018;16(6):765–78.
doi: 10.1007/s40258-018-0416-4
pubmed: 30094591
pmcid: 6467569
Koopmanschap MA, van Ineveld BM. Towards a new approach for estimating indirect costs of disease. Soc Sci Med. 1992;34(9):1005–10.
doi: 10.1016/0277-9536(92)90131-9
pubmed: 1631600
van den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis. 2010;69(Suppl 1):i89-91.
doi: 10.1136/ard.2009.117150
pubmed: 19995754
Statline C. Income, consumption, wealth of households: key figures; National Accounts 2021. Available from: https://opendata.cbs.nl/statline/#/CBS/en/dataset/84102ENG/table . (accessed on: Oct 27, 2021)
CBS. Average age of first-time mothers up to 29.9 years (in Dutch: Leeftijd moeder bij eerste kind stijgt naar 29,9 jaar) 2019. Available from: https://www.cbs.nl/nl-nl/nieuws/2019/19/leeftijd-moeder-bij-eerste-kind-stijgt-naar-29-9-jaar . (accessed on: Oct 26, 2021)
Beck E, Klint J, Neine M, Garcia S, Meszaros K. Cost-effectiveness of 4CMenB infant vaccination in England: a comprehensive valuation considering the broad impact of serogroup B invasive meningococcal disease. Value Health. 2021;24(1):91–104.
doi: 10.1016/j.jval.2020.09.004
pubmed: 33431159
Volksgezondheidenzorg.info. Participation. Figures&Context. Labour Participation [in Dutch: Participatie. Cijfers&Context. Arbeidsparticipatie] 2021. Available from: https://www.volksgezondheidenzorg.info/onderwerp/participatie/cijfers-context/arbeidsparticipatie#node-gezondheid-en-arbeidsparticipatie . (accessed on: Oct 26, 2021)
Brueggemann AB, Jansen van Rensburg MJ, Shaw D, et al. Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. Lancet Digital Health. 2021;3(6):e360–70.
doi: 10.1016/S2589-7500(21)00077-7
pubmed: 34045002
Subbarao S, Campbell H, Ribeiro S, et al. Invasive meningococcal disease, 2011–2020, and impact of the COVID-19 Pandemic, England. Emerg Infect Dis. 2021;27(9):2495–7.
doi: 10.3201/eid2709.204866
pubmed: 34193335
pmcid: 8386802
Clark S, Campbell H, Mensah AA, et al. An increase in Group B invasive meningococcal disease among adolescents and young adults in England following easing of COVID-19 containment measures. SSRN. 2021.
Hepkema H, Pouwels KB, van der Ende A, Westra TA, Postma MJ. Meningococcal serogroup A, C, W(1)(3)(5) and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands. PLoS One. 2013;8(5): e65036.
doi: 10.1371/journal.pone.0065036
pubmed: 23741448
pmcid: 3669019
Statistics Netherlands (Centraal Bureau voor de Statistiek). Vacancies (Vacatures) 2022. Available from: https://www.cbs.nl/nl-nl/visualisaties/dashboard-arbeidsmarkt/vacatures . (accessed on: Jan 25, 2022)
Statistics Netherlands (Centraal Bureau voor de Statistiek). Unemployed (Werklozen) 2022. Available from: https://www.cbs.nl/nl-nl/visualisaties/dashboard-arbeidsmarkt/werklozen . (accessed on: Jan 25, 2022)
Raad S-E. Werk: van belang voor iedereen. Een advies over werken met een chronische ziekte 2016. Available from: https://www.ser.nl/-/media/ser/downloads/adviezen/2016/werken-chronische-ziekte.pdf . (accessed on: Oct 26, 2021)
Middeldorp M, Steens A, Lagerweij G, et al. The burden of invasive meningococcal disease in the Netherlands, 2011–2020. Vaccine. 2023;41(16):2664–70.
doi: 10.1016/j.vaccine.2023.03.017
pubmed: 36933982
Viner RM, Booy R, Johnson H, et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012;11(9):774–83.
doi: 10.1016/S1474-4422(12)70180-1
pubmed: 22863608
Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R. The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J. 2013;32(1):e20–5.
doi: 10.1097/INF.0b013e3182706b89
pubmed: 22926207